ReviewClinical and translational allergy2018
An EAACI task force report: recognising the potential of the primary care physician in the diagnosis and management of drug hypersensitivity.
Review in Clinical and translational allergy, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 42 citations in OpenAlex.
- Review
- A survey of current management practices for delayed maculopapular exanthemas during antibiotic treatment among primary care pediatricians.Italian journal of pediatrics · 2025Article
- Is the Anamnesis Enough to De-Label Patients with Reported Beta-Lactam Allergy?Journal of clinical medicine · 2024Article
- Editorial: Drug allergy in children.Frontiers in allergy · 2024Article
- Recent findings on drug hypersensitivity in children.Frontiers in allergy · 2024Review
- A multidisciplinary approach to verify and de-label of drug allergic histories in a university hospital in Thailand: a retrospective descriptive study.Journal of pharmaceutical policy and practice · 2023Article
- Clinical review: The suggested management pathway for urticaria in primary care.Clinical and translational allergy · 2022Review
- Allergic and hypersensitivity conditions in non-specialist care: Flow diagrams to support clinical practice.Allergy · 2022Article
- mHealth and telemedicine utility in the monitoring of allergic diseases.Frontiers in allergy · 2022Review
- Usefulness of the drug allergy passport in the drug allergy management.Postepy dermatologii i alergologii · 2021Article
- Paracetamol Allergy: A Case of a 9-Year-Old Female with a History of Atopy.Pediatric allergy, immunology, and pulmonology · 2021Article
- Systemic reaction during intradermal skin tests with beta-lactams.BMJ case reports · 2021Article
- Knowledge gaps of drug allergy in children: a survey of primary care doctors.Postepy dermatologii i alergologii · 2021Article
- Model Based Evaluation of Hypersensitivity Adverse Drug Reactions to Antimicrobial Agents in Children.Frontiers in pharmacology · 2021Review
- Diagnostic procedures & practices in drug allergy/hypersensitivity: a survey of 13 Asian countries.Asia Pacific allergy · 2020Article
- The Potential of Clinical Decision Support Systems for Prevention, Diagnosis, and Monitoring of Allergic Diseases.Frontiers in immunology · 2020Review
- Future research trends in understanding the mechanisms underlying allergic diseases for improved patient care.Allergy · 2019Review
- Management of the child with allergy to non-antibiotic drugs.Acta bio-medica : Atenei Parmensis · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 6 institutions in 4 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Adverse drug reactions include drug hypersensitivity reactions (DHRs), which can be immunologically mediated (allergy) or non-immunologically mediated. The high number of DHRs that are unconfirmed and often self-reported is a frequent problem in daily clinical practice, with considerable impact on future prescription choices and patient health. It is important to distinguish between hypersensitivity and non-hypersensitivity reactions by adopting a structured diagnostic approach to confirm or discard the suspected drug, not only to avoid life-threatening reactions, but also to reduce the frequent over-diagnosis of DHRs. Primary care physicians are often the first point of contact for the sufferer of a reaction, as such they have a key role in deciding whether to discard the diagnosis or send the patient for further investigation. In this review, we highlight the importance of diagnosing DHRs, analysing in detail the role of primary care physicians. We describe the common patterns of DHRs and signs of its progression, as well as the indications and contraindications for referring the patient to an allergist. The diagnostic process is described and the possible tests are discussed, which often depend on the drug involved and the type of DHR suspected. We also describe recommendations regarding the avoidance of medication suspected to have caused the reaction and the use of alternatives.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.